Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, 18 years old, with type 2 diabetes and with inadequate glycemic control~* Drug naive or treated with anti-diabetic medication for \< 24 weeks~* C-peptide ≥ 1.0 ng/mL~* Body Mass Index ≤ 45.0 kg/m²~Exclusion Criteria:~* AST and/or ALT \> 3 times ULN~* Serum total bilirubin \> 2 mg/dL~* Serum creatinine ≥ 1.50 mg/dL for men or ≥ 1.40 mg/dL for women~* Creatine kinase ≥ 3 times ULN~* Symptoms of severely uncontrolled diabetes~* Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): None
- Group 2 (Type: EXPERIMENTAL): None
- Group 3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).